These free independent resources are aimed at educating neurologists, diabetologists, endocrinologists and other members of the MDT who manage diabetic patients with history or risk of stroke, on the benefits of newer drug classes such as GLP-1RAs in the primary and secondary prevention of stroke.
The program comprises an interactive eLearning module and a searchable webcast recording (with bonus features) from a symposium at the 7th European Stroke Conference (ESOC 2021).
This program is suitable for neurologists, diabetologists, endocrinologists, cardiologists, primary care practioners and those in the multidisciplinary team treating stroke patients.
UMC Utrecht Brain Center, Utrecht, The Netherlands
Geert Jan Biessels obtained his PhD in 1997 at Utrecht University, registered as a neurologist in 2004, and was appointed Professor of Cerebrovascular Disease and Cognition in 2012. His area of expertise is vascular cognitive impairment (VCI) and small vessel disease (SVD), focusing on novel imaging markers to improve diagnosis and prognostication and to identify targets for personalized treatment and the role of diabetes.
Professor Biessels is actively involved in several national and international VCI and SVD research networks, including STRIVE and HARNESS. He leads the Dutch Heart Brain Connection consortium and the international Meta VCI Map consortium (https://metavcimap.org/). He was Principal Investigator in two large randomized controlled trials in diabetes with cognitive outcomes. He participates in the H2020 programs SVDs@target and Recognised.
Professor Biessels has mentored over 40 PhD students and has over 350 peer-reviewed publications. He is a Dutch Research Council Vidi and Vici laureate and received the senior investigator award of the European Stroke Organisation in 2015.
In 2019 and 2020 he served as member of the ESOC Scientific Abstracts Committee. In 2021 and 2022 he had the honour to serve on the ESOC Program Committee.
Consults for Eli Lilly and receives research support from Boehringer Ingelheim. All financial compensation for these services is transferred to his employer, the UMCU.
La Paz University Hospital, Madrid, Spain
Dr Fuentes’ current position is Stroke Unit Division Head at the Department of Neurology and Stroke Unit of La Paz University Hospital Madrid, Spain and Associate Professor (Department of Medicine), School of Medicine, Universidad Autónoma de Madrid, Spain.
Dr Fuentes has been a Fellow of the ESO since November 2016 and is a researcher at the Neurosciences Area of the IdiPAZ Health Research Institute. She has been a member of the Madrid Stroke Network and of the advisory board of the Madrid Health Government for the development and follow-up of the Madrid Stroke Plan since 2014. She has been author of the European Stroke Organisation Guidelines for the management of glucose in acute stroke patients (Eur J Stroke 2018) and of the Spanish Society of Neurology recommendations for stroke prevention in patients with diabetes.
Dr Fuentes research is focused on the treatment of acute stroke, the prognostic influence of hyperglycaemia and diabetes in acute stroke, the development of efficient acute stroke models and stroke prevention. She has a specific interest in translational research in stroke and has been a member of the research team at the Cerebrovascular Diseases and Neurosciences Research Laboratory at the IdiPAZ Health Research Institute, where she has collaborated in the development of preclinical and clinical trials on brain repair therapies.
Honoraria or consultation fees: Novo Nordisk, BMS-Pfizer
McMaster University, Hamilton, Ontario, Canada
Dr Hertzel C. Gerstein is a Professor at McMaster University and Hamilton Health Sciences, where he holds the Population Health Research Institute Chair in Diabetes and is Director of the Diabetes Care and Research Program and Deputy Director of the Population Health Research Institute.
Dr Gerstein’s research has been published in over 400 papers, spans 50 countries and has been funded by the NIH, the Canadian Institutes of Health Research, the Heart and Stroke Foundation of Canada, the Canadian Diabetes Association and the pharmaceutical industry. His research focuses on five key areas: a) the prevention and therapy of diabetes and its many consequences; b) the relationship between dysglycemia (a term he coined in 1995), cardiovascular outcomes, cognitive impairment, other diabetes-related chronic consequences and new diabetes; c) strategies for type 2 diabetes remission; d) novel biomarkers for cardiovascular disease in diabetes; and e) the biologic basis of glucose-related health consequences. In 2016 he produced and distributed a music video to mitigate the impact of diabetes on affected people and their families. In 2012 he received the Canadian Diabetes Association’s Lifetime Achievement Award.
Grants/research support: Eli Lilly, Astra Zeneca, Sanofi, Merck, Novo Nordisk; Honoraria or consultation fees: Eli Lilly, Boehringer Ingleheim, Sanofi, Novo Nordisk, Abbott, Pfizer, COVANCE, Kowa, DKSH, Zuellig
Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada
Professor Stewart Harris holds the Diabetes Canada Chair in Diabetes Management. His research career has focused on identifying and closing the care gap for disadvantaged Canadians with diabetes. His pioneering work carved new understandings of the pathophysiology and epidemiology of diabetes in Canada’s Indigenous Peoples. His research has also had widespread impacts on therapeutic development and management in primary care. His other areas of interest include the epidemiology of hypoglyemcia and pragmatic clinical trials.
He has received numerous awards for his work including being appointed to the Order of Canada in 2015 for his contributions to developing diabetes prevention strategies in Indigenous communities and other vulnerable populations. He has published over 280 articles. Dr. Harris’s internationally recognized career reflects a passionate commitment to medicine, science, and mentorship.
Grants/research support: Abbott, Applied Therapeutics Inc., AstraZeneca, Canadian Institutes for Health Research (CIHR), Eli Lilly, Health Canada/First Nations and Inuit Health Branch, Janssen, Juvenile Diabetes Research Foundation (JDRF), Novo Nordisk, Sanofi, The Lawson Foundation; Honoraria or consultation fees: Abbott, AstraZeneca, Bayer Inc., Eli Lilly, HLS Therapeutics, Janssen, Novo Nordisk, Sanofi
The live symposium at ESOC 2021 titled: New perspectives in the multidisciplinary management of stroke associated with diabetes, London, United Kingdom, (03/09/2021) has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 1 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.
Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 CreditsTM. Information on the process to convert EACCME® credit to AMA credit can be found at www.ama-assn.org/education/earn-credit-participation-international-activities.
Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.
This program has been made possible with an educational grant from Novo Nordisk A/S.
Please wait while you are redirected to the right page...